# A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors

> **NCT04175847** · PHASE1,PHASE2 · COMPLETED · sponsor: **RemeGen Co., Ltd.** · enrollment: 198 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** RC88

## Key facts

- **NCT ID:** NCT04175847
- **Lead sponsor:** RemeGen Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-14
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04175847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04175847, "A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04175847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*